Studies with antiparkinsonian drugs with chronic psychiatric patients.
D000328:Adult; D000368:Aged; D002746:Chlorpromazine / Q000009:adverse effects*; D005116:Extrapyramidal Tracts; D006801:Humans; D001523:Mental Disorders; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D010276:Parasympatholytics / Q000627:therapeutic use*; D010919:Placebos / Q000627:therapeutic use; D014268:Trifluoperazine / Q000009:adverse effects*; D014282:Trihexyphenidyl / Q000627:therapeutic use*
D010276:Parasympatholytics; D010919:Placebos; D014268:Trifluoperazine; D014282:Trihexyphenidyl; D002746:Chlorpromazine